<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46108">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02505984</url>
  </required_header>
  <id_info>
    <org_study_id>2015P001100</org_study_id>
    <secondary_id>224421</secondary_id>
    <secondary_id>225686</secondary_id>
    <nct_id>NCT02505984</nct_id>
  </id_info>
  <brief_title>Preventing Postpartum Depression With Intranasal Oxytocin</brief_title>
  <acronym>IN-OXT</acronym>
  <official_title>Testing the Efficacy of Intranasal Oxytocin for the Prevention of Postpartum Depression and PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this feasibility study is to test a new treatment for preventing
      childbirth-related mental illness in postpartum mothers. The treatment is aimed at enhancing
      maternal bonding and reducing postpartum depression (PPD) and posttraumatic stress symptoms
      in mothers at risk. To this end, the investigators will test the clinical utility of
      intranasal oxytocin (IN-OXT) administered to mothers during the first postpartum days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postpartum depression (PPD) is a debilitating disorder which imposes a threat to mother and
      infant heath. An estimated 600,000 American women suffer from PPD annually, making it one of
      the most frequent complications of pregnancy. Available secondary preventing interventions
      are often ineffective, which call for identifying novel means for prevention. Impaired
      mother-infant bonding is a hallmark of PPD. Depressed mothers may have difficulties
      developing maternal feelings and providing sensitive care. In turn, impaired bonding may
      worsen mother's depression. Posttraumatic symptoms following childbirth may over lap with
      the depression and complicate maternal bonding. Conventional pharmacotherapy does not help
      with bonding impairment.

      This feasibility study will attempt to fill in the current gap in effective preventive
      interventions for pregnant mothers at risk. Recent evidence in postpartum mothers indicates
      that high peripartum oxytocin levels are associated with enhanced maternal behavior and low
      levels with depression.Therefore, the investigators will test the therapeutic effects of
      oxytocin (OXT). It is hypothesized that administration of intranasal oxytocin (IN-OXT)
      (total daily dose 48 IU) over the course of four days from as early as day one postpartum in
      comparison to placebo will 1) enhance mother-infant bonding, and 2) reduce depressive and
      posttraumatic symptoms at 5 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depression symptoms</measure>
    <time_frame>Day 5 postpartum</time_frame>
    <description>Edinburgh Postnatal Depression Scale (EPDS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mother-infant bonding</measure>
    <time_frame>Day 5 postpartum</time_frame>
    <description>Postpartum Bonding Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Posttraumatic stress symptoms</measure>
    <time_frame>Day 5 postpartum</time_frame>
    <description>PTSD checklist for DSM 5</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Depression, Postpartum</condition>
  <condition>Posttraumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sub-group of participants receiving oxytocin nasal spray (Syntocinon)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sub-group of participants receiving placebo nasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Study participants will be randomized to a placebo or drug group.</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Study participants will be randomized to a placebo or drug group.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Third-trimester pregnant women being followed at the MGH Obstetrics Program

          -  At risk of postpartum depression (PPD)

        Exclusion Criteria:

          -  Failure to participate in regular prenatal check-ups

          -  Current diagnosis of psychosis

          -  Obstetric complication (e.g., preeclampsia, excessive hemorrhaging)

          -  Use of potentially confounding or interacting medications

          -  Complicating pediatric medical condition in the newborn.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Dekel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hosptial</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sharon Dekel, PhD</last_name>
    <phone>617-726-1352</phone>
    <email>sdekel@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hosptial</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Dekel, PhD</last_name>
      <phone>617-726-1352</phone>
      <email>sdekel@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mah BL, Bakermans-Kranenburg MJ, Van IJzendoorn MH, Smith R. Oxytocin promotes protective behavior in depressed mothers: a pilot study with the enthusiastic stranger paradigm. Depress Anxiety. 2015 Feb;32(2):76-81. doi: 10.1002/da.22245. Epub 2014 Feb 12.</citation>
    <PMID>24523054</PMID>
  </reference>
  <reference>
    <citation>Skrundz M, Bolten M, Nast I, Hellhammer DH, Meinlschmidt G. Plasma oxytocin concentration during pregnancy is associated with development of postpartum depression. Neuropsychopharmacology. 2011 Aug;36(9):1886-93. doi: 10.1038/npp.2011.74. Epub 2011 May 11.</citation>
    <PMID>21562482</PMID>
  </reference>
  <reference>
    <citation>Fewtrell MS, Loh KL, Blake A, Ridout DA, Hawdon J. Randomised, double blind trial of oxytocin nasal spray in mothers expressing breast milk for preterm infants. Arch Dis Child Fetal Neonatal Ed. 2006 May;91(3):F169-74. Epub 2005 Oct 13.</citation>
    <PMID>16223754</PMID>
  </reference>
  <reference>
    <citation>Riem MM, Bakermans-Kranenburg MJ, Pieper S, Tops M, Boksem MA, Vermeiren RR, van Ijzendoorn MH, Rombouts SA. Oxytocin modulates amygdala, insula, and inferior frontal gyrus responses to infant crying: a randomized controlled trial. Biol Psychiatry. 2011 Aug 1;70(3):291-7. doi: 10.1016/j.biopsych.2011.02.006. Epub 2011 Apr 5. Erratum in: Biol Psychiatry. 2012 Apr 1;71(7):660.</citation>
    <PMID>21470595</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 21, 2017</lastchanged_date>
  <firstreceived_date>July 19, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Sharon Dekel, PhD</investigator_full_name>
    <investigator_title>Instructor in Psychology</investigator_title>
  </responsible_party>
  <keyword>oxytocin, bonding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Depression, Postpartum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
